Immusoft
Immusoft develops cell therapies that program patients’ own B cells to produce therapeutic proteins for sustained delivery. Its therapies are intended for people with rare and other diseases with significant unmet need.
Facts
- HQ
- Seattle
- Sectors
- Biotechnology Research
- Founded
- 2009
- Type
- Corporation Seattle business license
- Employees
- 21
- Registered name
- Immusoft Corp Seattle business license
- Stage
- Series B
- Members see funding amounts. .
- Founders
- Matthew Scholz
Is this your organization? Claim it
Immusoft and Takeda partner on B‑cell protein therapies for CNS disorders in deal potentially worth over $900M
Seattle cell therapy startup Immusoft struck a collaboration with Takeda to develop B‑cell–based protein therapies for central nervous system disorders in a deal that could be worth over $900 million. Immusoft will get research funding, an undisclosed upfront payment and option/milestone fees, while Takeda can license preclinical programs and advance products to clinic and commercialization.
OncoSenX raises $3M to advance non-viral, gene-delivery cancer therapeutics targeting solid tumors
Seattle startup OncoSenX raised $3 million to advance a non-viral, lipid nanoparticle gene-delivery platform that aims to selectively kill solid tumor cells based on their genetic mutations, and plans to use the funding to accelerate preclinical work toward Phase 1 trials.
Immusoft raises $20M Series B to advance ISP gene therapy and push ISP-001 into Phase I/II for MPS I
Seattle biotech Immusoft raised $20 million in a Series B round to advance its immune system programming (ISP) gene therapy platform, aiming to move lead candidate ISP-001 into Phase I/II trials for MPS I and generate initial safety and efficacy data in 2019; ISP uses patients' blood cells modified to secrete therapeutic proteins and has FDA orphan and rare pediatric disease designations. The company credits progress under new CEO Sean Ainsworth, who replaced founder Matthew Scholz as CEO last year (Scholz is now CTO), and says the platform could broadly replace recombinant enzyme replacement therapies.
By Immusoft
See all 7Immusoft to Present Positive First-in-Human Data for ISP-001 Engineered B Cell Therapy in MPS I at ASGCT 2026
Immusoft will present positive clinical data showing favorable safety, tolerability, biochemical activity, and safe re-dosing for ISP-001, the world’s first engineered autologous B cell therapy for MPS I, supporting continued adult development and planned pediatric expansion.
Immusoft explores scientific, ethical, regulatory, and practical considerations shaping pediatric cell and gene therapy clinical trial design
This article examines the scientific, ethical, regulatory, and practical factors that influence the design of pediatric cell and gene therapy (CGT) clinical trials, highlighting challenges and considerations specific to children. It aims to guide researchers and stakeholders in creating trials that balance safety, efficacy, and ethical responsibilities for pediatric populations.
Immusoft to Present World’s First Patient Treated with Engineered B Cell Therapy ISP-001 Showing Safe Re-dosing and Early Efficacy
Immusoft will present the world’s first clinical case of an engineered B cell therapy (ISP-001) treating MPS I, reporting favorable safety, the ability to safely re-dose, and early pharmacodynamic and functional improvements in treated patients.
People
-
Sean Ainsworth Executive, Executive Officer, Director, Chief Executive Officer
-
Scott McIvor Executive, Chief Development Officer
Online
Questions about Immusoft
What is Immusoft?
immusoft.com
Who are the people behind Immusoft?
Seattle Flow lists Sean Ainsworth (Executive, Executive Officer, Director, Chief Executive Officer) and Scott McIvor (Executive, Chief Development Officer) at Immusoft.
Who invested in Immusoft, and how much has it raised?
Members of Seattle Flow see Immusoft's funding rounds, amounts and investors on its Funding tab. Joining is free.
Where is Immusoft based?
Immusoft is headquartered in Seattle.
When was Immusoft founded?
Immusoft was founded in 2009.
How many people work at Immusoft?
Immusoft has 21 employees.